US Patent

US9006224 — Neuroendocrine tumor treatment

Method of Use · Assigned to Novartis AG · Expires 2028-07-01 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.

USPTO Abstract

A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.

Drugs covered by this patent

Afinitor (everolimus) · Novartis

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1681`	—	Afinitor
`U-1681`	—	Afinitor
`U-1681`	—	Afinitor
`U-1681`	—	Afinitor

Patent Metadata

Patent number: US9006224
Jurisdiction: US
Classification: Method of Use
Expires: 2028-07-01
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.